This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 43475 results found since Jan 2013.

BET 1: Propofol for migraine
A short-cut review was carried out to establish whether propofol can improve recovery and reduce recurrence in patients presenting to the emergency department with acute migraine. Three studies were directly relevant to the question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these papers are shown in table 1. The clinical bottom line is that propofol might be a safe and effective therapy in the treatment of migraine, but more well-designed trials are needed to compare with standard therapy before widespread use is considered.
Source: Emergency Medicine Journal - July 19, 2013 Category: Emergency Medicine Tags: EMJ Best evidence topic reports, Headache (including migraine) Source Type: research

Canadian headache society guideline acute drug therapy for migraine headache.
PMID: 23968886 [PubMed - in process]
Source: The Canadian Journal of Neurological Sciences - September 1, 2013 Category: Neurology Authors: Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker WJ, On Behalf Of The Canadian Headache Society Acute Migraine Treatment Guideline Development Group Tags: Can J Neurol Sci Source Type: research

First device to prevent migraine headaches wins FDA approval
The US Food and Drug Administration has given its first approval for the marketing of a device for preventing migraine headaches. The federal agency says the device, which comes in the form of a headband that delivers a nerve-stimulating low electrical current, may bring relief to patients who cannot tolerate current migraine drugs."This is also the first transcutaneous electrical nerve stimulation device specifically authorized for use prior to the onset of pain," they told the press.
Source: Health News from Medical News Today - March 12, 2014 Category: Consumer Health News Tags: Headache / Migraine Source Type: news

Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine
Conclusions: Valproate was less efficacious than either metoclopramide or ketorolac. Metoclopramide demonstrated superiority to ketorolac on several endpoints. Classification of evidence: This study provides Class I evidence that in ED patients with acute migraine, IV valproate is inferior to metoclopramide or ketorolac in improving headache outcomes.
Source: Neurology - March 17, 2014 Category: Neurology Authors: Friedman, B. W., Garber, L., Yoon, A., Solorzano, C., Wollowitz, A., Esses, D., Bijur, P. E., Gallagher, E. J. Tags: Migraine, Clinical trials Randomized controlled (CONSORT agreement), Class I ARTICLE Source Type: research

PRRT2 and hemiplegic migraine: A complex association
Hemiplegic migraine (HM) is a rare migraine subtype characterized by hemiparesis during the attack and is associated with at least 3 genes: CACNA1A, ATP1A2, and SCN1A.1 Recent reports suggested that the proline-rich transmembrane protein PRRT2 gene might be the fourth gene for HM.2 In the vast majority of cases, PRRT2 is associated with paroxysmal kinesigenic dyskinesia, benign familial infantile seizures (BFIS), or infantile convulsion choreoathetosis syndrome. In families with such a "typical PRRT2 phenotype," HM was reported in a few PRRT2 mutation carriers. Most of these cases also had a "typical PRRT2 phenotype."2 Vic...
Source: Neurology - July 14, 2014 Category: Neurology Authors: Pelzer, N., de Vries, B., Kamphorst, J. T., Vijfhuizen, L. S., Ferrari, M. D., Haan, J., van den Maagdenberg, A. M. J. M., Terwindt, G. M. Tags: Migraine, All Movement Disorders, All Epilepsy/Seizures, Association studies in genetics, Ion channel gene defects CLINICAL/SCIENTIFIC NOTES Source Type: research

Eager for better migraine therapies: Keep your (telcage)PANTs on
Pharmacologic therapies for migraine have traditionally been divided into 2 broad and distinct categories.1–3 Acute treatments are given at the time of a migraine attack to relieve pain and restore function. Preventive treatments are usually taken on a daily basis to reduce the frequency of headaches. Conventional wisdom suggests that the drugs used as acute treatments (i.e., triptans, ergot alkaloids, nonsteroidal anti-inflammatory agents) differ from the drugs used as preventive treatments (antiepilepsy drugs, β-blockers, calcium channel blockers, and antidepressants) in mechanism of action, pharmacokinetic pr...
Source: Neurology - September 8, 2014 Category: Neurology Authors: Lipton, R. B., Sandor, P. S. Tags: All Headache, Migraine EDITORIALS Source Type: research

Reduced trigeminovascular cyclicity in patients with menstrually related migraine
Conclusions: Our study provides evidence for a reduced menstrual cyclicity of both estradiol levels and the trigeminovascular vasodilator system in patients with MRM.
Source: Neurology - January 12, 2015 Category: Neurology Authors: Ibrahimi, K., van Oosterhout, W. P. J., van Dorp, W., Danser, A. H. J., Garrelds, I. M., Kushner, S. A., Lesaffre, E. M. E. H., Terwindt, G. M., Ferrari, M. D., van den Meiracker, A. H., MaassenVanDenBrink, A. Tags: Migraine, Other cerebrovascular disease/ Stroke, All Clinical Neurology ARTICLE Source Type: research

Ictal adipokines are associated with pain severity and treatment response in episodic migraine
Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.
Source: Neurology - April 6, 2015 Category: Neurology Authors: Chai, N. C., Gelaye, B., Tietjen, G. E., Dash, P. D., Gower, B. A., White, L. W., Ward, T. N., Scher, A. I., Peterlin, B. L. Tags: Migraine, All Pain ARTICLE Source Type: research

Comment: Tackling shared genetic underpinnings of migraine and ischemic stroke
In this large collaborative effort, Malik et al.1 explore shared genetic variation underlying 2 common conditions: migraine and ischemic stroke (IS). Numerous studies have shown an increased risk of stroke in patients with migraine, but the contribution of genetic factors to this relationship is unclear.2 The authors used the 2 largest existing meta-analyses of genome-wide association studies (GWAS) for both phenotypes.
Source: Neurology - May 25, 2015 Category: Neurology Authors: Debette, S. Tags: Migraine, All Cerebrovascular disease/Stroke, Case control studies, All Genetics, Association studies in genetics ARTICLE Source Type: research

Teaching NeuroImages: Red forehead dot syndrome and migraine revisited
A 32-year-old woman with episodic headaches presented with 1.5 months of continuous left frontotemporal headache, pain, and dragging sensation in the left eye. Red forehead dot was noted along with eyelid ecchymosis (figures 1 and 2). Family history of migraine was reported in the patient's father and grandmother. Neurologic examination and brain MRI, magnetic resonance angiography, and magnetic resonance venography had normal results and workup revealed no evidence for vasculitis. Activation of the trigeminovascular system leading to release of vasoactive peptides is the likely cause of the red forehead dot and eyelid ecc...
Source: Neurology - July 20, 2015 Category: Neurology Authors: Sethi, P. K., Sethi, N. K., Torgovnick, J. Tags: All Headache, Migraine RESIDENT AND FELLOW SECTION Source Type: research

Interictal cerebral and systemic endothelial dysfunction in patients with migraine: a case-control study
Conclusions Migraineurs may have isolated cerebral endothelial dysfunction restricted to the posterior circulation in the absence of systemic endothelial dysfunction.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Rajan, R., Khurana, D., Lal, V. Tags: Headache (including migraine), Pain (neurology) Source Type: research

Comment: Outcomes of migraine therapy with IV dihydroergotamine
IV dihydroergotamine (DHE) is a widely used treatment for status migrainosus or refractory chronic migraine, but there are few published studies on outcomes of this therapy.1 The report by Eller et al.2 adds to our current understanding of the effects of DHE, with a thorough description of their experience at an academic inpatient headache unit. Although the observations are retrospective, this kind of careful documentation and systematic reporting of patient experience can be enormously valuable in characterizing "real world" patient management issues. One such issue is the transient worsening of headache associated with ...
Source: Neurology - February 29, 2016 Category: Neurology Authors: Charles, A. Tags: Migraine, Class IV ARTICLE Source Type: research

Women with Migraine Face Increased CV Risk
–But clinical implications are unclear since there’s no known mechanism Women who have migraine headaches have a significantly increased risk of cardiovascular disease, according to new results from a large observational study published in the BMJ. Earlier studies have established a strong link between migraine and stroke, which the the new study now extends to...Click here to continue reading...
Source: CardioBrief - May 31, 2016 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes Cardiovascular disease migraine stroke women Source Type: blogs

TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
Conclusions: TEV-48125 demonstrated a significant improvement within 1 week of therapy initiation in patients with CM. Classification of evidence: This study provides Class II evidence that for patients with CM, TEV-48125 significantly decreases the number of headache hours within 3 to 7 days of injection.
Source: Neurology - July 3, 2016 Category: Neurology Authors: Bigal, M. E., Dodick, D. W., Krymchantowski, A. V., VanderPluym, J. H., Tepper, S. J., Aycardi, E., Loupe, P. S., Ma, Y., Goadsby, P. J. Tags: Migraine ARTICLE Source Type: research

Comment: Monoclonal antibodies in chronic migraine--Are early effects meaningful?
Chronic migraine affects approximately 1% of the adult population and is defined as headache on ≥15 d/mo with ≥8 days of migraine-type headache. Since treatment often remains frustrating for both the patient and physician, new treatment strategies are highly welcome.
Source: Neurology - July 3, 2016 Category: Neurology Authors: Limmroth, V. Tags: Migraine ARTICLE Source Type: research